HYPORT:3周大分割术后放疗治疗头颈部鳞状细胞癌的1期研究
这项1期研究纳入完全切除的Ⅰ-ⅣB期口腔、口咽、下咽或喉鳞状细胞癌且有中危因素的患者,评估术后中度大分割放疗的安全性。0水平为46.5 Gy分15次每周5天,1水平为44.4 Gy分12次每周4天,各6例;最大耐受剂量/分割方案确定为44.4 Gy分12次,但基于等效生物有效剂量下耐受性更佳,推荐2期剂量/分割方案为46.5 Gy分15次。
要点
- 12例患者中无剂量限制性毒性,无4-5级毒性。
- 0水平急性3级毒性2例(体重下降、颈部脓肿),1水平3例(均为口腔黏膜炎)。
- 推荐2期剂量/分割方案为46.5 Gy分15次,实验臂将采用该方案。
核心结论
- 术后3周中度大分割放疗在该1期头颈部鳞状细胞癌队列中短期耐受良好。
- 最大耐受剂量/分割方案确定为44.4 Gy分12次,但推荐2期剂量/分割方案为46.5 Gy分15次。
- 后续2期随机试验的实验臂将采用46.5 Gy分15次。
研究设计与样本
- 1期研究采用滚动6例设计,纳入完全切除的Ⅰ-ⅣB期口腔、口咽、下咽或喉鳞状细胞癌且有中危因素的患者。
- 中危因素包括T3/4期病变、阳性淋巴结、切缘近、神经周围侵犯和/或淋巴血管侵犯。
- 0水平为46.5 Gy分15次每周5天,1水平为44.4 Gy分12次每周4天,各纳入6例。
- 主要终点为术后中度大分割放疗的最大耐受剂量/分割方案。
主要发现
- 共12例患者入组,0水平和1水平各6例。
- 无患者发生剂量限制性毒性或4-5级毒性。
- 0水平2例发生急性3级毒性(体重下降、颈部脓肿),1水平3例发生急性3级毒性(均为口腔黏膜炎)。
- 0水平1例发生晚期3级毒性(持续性颈部脓肿)。
- 中位随访18.6个月,1水平2例复发:1例为原发灶偏外侧扁桃体的对侧未清扫未照射颈部区域复发,1例为口腔舌原发灶的野内局部复发。
关键数值与推荐
- 最大耐受剂量/分割方案为44.4 Gy分12次。
- 基于等效生物有效剂量下耐受性更佳,推荐2期剂量/分割方案为46.5 Gy分15次。
- 后续2期随机试验实验臂将采用46.5 Gy分15次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Shortening the overall radiation therapy (RT) treatment time has advantages in cost and treatment burden, but data on hypofractionated RT in head and neck squamous cell carcinoma are limited. This study assessed the safety of moderately hypofractionated RT in the postoperative setting. METHODS AND MATERIALS: Patients with completely resected stage I-IVB squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx with intermediate risk factor(s) including T3/4 disease, positive lymph node(s), close margin(s), perineural invasion, and/or lymphovascular invasion were enrolled on a rolling 6-design phase 1 study. Levels 0 and 1 consisted of 46.5 Gy in 15 fractions delivered 5 days a week and 44.4 Gy in 12 fractions delivered 4 days a week, respectively. The primary endpoint was maximum tolerated dose/fractionation of moderately hypofractionated postoperative RT. RESULTS: Twelve patients were enrolled with 6 each on levels 0 and 1. No patient experienced a dose-limiting toxicity or grade 4 to 5 toxicity. Acute grade 3 toxicity occurred in 2 patients on level 0 (weight loss, neck abscess) and 3 patients on level 1 (all oral mucositis). One patient on level 0 experienced late grade 3 toxicity (persistent neck abscess). With a median follow-up of 18.6 months, 2 patients on level 1 had a recurrence: a regional recurrence in the undissected, unirradiated contralateral neck from a well-lateralized tonsil primary and an in-field local recurrence of oral tongue primary. The maximum tolerated dose/fractionation was determined to be 44.4 Gy in 12 fractions, but owing to more favorable tolerability in the setting of equivalent biologically effective dose, 46.5 Gy in 15 fractions was deemed the recommended phase 2 dose/fractionation. CONCLUSIONS: Moderately hypofractionated RT delivered over 3 weeks is well tolerated in the short term in this phase 1 cohort of patients with head and neck squamous cell carcinoma following surgical resection. The follow-up phase 2 randomized trial will deliver 46.5 Gy in 15 fractions as the experimental arm.
引用
- Moon DH, Avkshtol V, Vo D, et al. HYPORT: Phase 1 Study of 3-Week Hypofractionated Postoperative Radiation Therapy for Head and Neck Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2023. PMID: 37380084. doi:10.1016/j.ijrobp.2023.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。